{
    "pmcid": "9792944",
    "qa_pairs": {
        "What is a key design consideration for SARS-CoV-2 nanobody binders according to the study?": [
            "Targeting conserved epitopes on the RBD that are less prone to mutations.",
            "Focusing on epitopes that are highly variable across different variants.",
            "Designing nanobodies to bind exclusively to the ACE2 receptor.",
            "Prioritizing nanobodies that bind to the nucleocapsid protein."
        ],
        "What is the mechanism by which the nanobody 3-2A2-4 neutralizes SARS-CoV-2?": [
            "Interfering with the structural transition of the RBD from the 'down' to 'up' conformation.",
            "Blocking the ACE2 binding site directly.",
            "Inhibiting the fusion of the viral envelope with the host cell membrane.",
            "Preventing the cleavage of the spike protein by host proteases."
        ],
        "What was demonstrated by the passive delivery of the nanobody 3-2A2-4 in K18-hACE2 mice?": [
            "Protection from infection with authentic SARS-CoV-2 Delta and Omicron variants.",
            "Increased susceptibility to SARS-CoV-2 infection.",
            "No effect on the progression of SARS-CoV-2 infection.",
            "Enhanced replication of SARS-CoV-2 in the host."
        ],
        "What was the source of the nanobodies that exhibited broad neutralizing activity against SARS-CoV-2 variants and other sarbecoviruses?": [
            "An alpaca immunized with the receptor-binding domain and spike protein of SARS-CoV-2.",
            "A camel immunized with the nucleocapsid protein of SARS-CoV-2.",
            "A llama immunized with the spike protein of SARS-CoV-1.",
            "A rabbit immunized with the membrane protein of SARS-CoV-2."
        ],
        "Which specific nanobody was highlighted for its structural insights and mechanism of action against SARS-CoV-2?": [
            "3-2A2-4",
            "4-3B1-5",
            "2-1C3-7",
            "5-4D2-6"
        ]
    }
}